Cytokinetics (CYTK) Stock Forecast & Price Target

Compare

1,243 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CYTK Analyst Ratings

Strong Buy

15 Buy

2 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Cytokinetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CYTK Stock 12 Month Forecast

Average Price Target

$92.79

▲(49.20% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $92.79 with a high forecast of $136.00 and a low forecast of $67.00. The average price target represents a 49.20% change from the last price of $62.19.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","137":"$137","56.75":"$56.8","83.5":"$83.5","110.25":"$110.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":136,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$136.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92.79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$92.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$67.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,56.75,83.5,110.25,137],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.43,67.16615384615385,72.90230769230769,78.63846153846154,84.37461538461538,90.11076923076922,95.84692307692308,101.58307692307692,107.31923076923076,113.05538461538461,118.79153846153847,124.52769230769229,130.26384615384615,{"y":136,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.43,63.84230769230769,66.25461538461539,68.66692307692308,71.07923076923078,73.49153846153847,75.90384615384616,78.31615384615385,80.72846153846154,83.14076923076924,85.55307692307693,87.96538461538462,90.37769230769231,{"y":92.79,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.43,61.85846153846154,62.286923076923074,62.715384615384615,63.143846153846155,63.57230769230769,64.00076923076924,64.42923076923077,64.8576923076923,65.28615384615385,65.71461538461539,66.14307692307692,66.57153846153847,{"y":67,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.92,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.21,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.84,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.43,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$136.00

Average Price Target$92.79

Lowest Price Target$67.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Salim Syed

Mizuho Securities

$84→$100

Buy

60.80%

Upside

Assigned

03/18/26

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Perspective Therapeutics (NYSE MKT: CATX)

Tessa Romero

J.P. Morgan

$74→$75

Buy

20.60%

Upside

Assigned

03/17/26

JPMorgan ups Cytokinetics target, adds to Analyst Focus ListJPMorgan ups Cytokinetics target, adds to Analyst Focus List

James Condulis

Stifel Nicolaus

$98

Buy

57.58%

Upside

Reiterated

03/17/26

Cytokinetics (CYTK) Gets a Buy from Stifel Nicolaus

Emily Field

Barclays

$87

Buy

39.89%

Upside

Reiterated

03/16/26

Barclays Keeps Their Buy Rating on Cytokinetics (CYTK)

Mayank Mamtani

B. Riley Securities

$108

Buy

73.66%

Upside

Reiterated

03/11/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pliant Therapeutics (NASDAQ: PLRX) and Cytokinetics (NASDAQ: CYTK)

Yasmeen Rahimi

Piper Sandler

$107

Buy

72.05%

Upside

Reiterated

03/09/26

Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Doximity (DOCS)

Ashwani Verma

UBS

$61→$69

Hold

10.95%

Upside

Reiterated

03/06/26

UBS Remains a Hold on Cytokinetics (CYTK)

Leonid Timashev

RBC Capital

$101

Buy

62.41%

Upside

Reiterated

03/05/26

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), Ascendis Pharma (NASDAQ: ASND) and Avalo Therapeutics (NASDAQ: AVTX)

Jason Zemansky

Bank of America Securities

$66→$67

Hold

7.73%

Upside

Reiterated

02/25/26

Cytokinetics price target raised to $67 from $66 at BofACytokinetics price target raised to $67 from $66 at BofA

Jason Butler

Citizens JMP

$88→$96

Buy

54.37%

Upside

Reiterated

02/25/26

Cytokinetics price target raised to $96 from $88 at CitizensCytokinetics price target raised to $96 from $88 at Citizens

Joseph Pantginis

H.C. Wainwright

$136

Buy

118.68%

Upside

Reiterated

02/25/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Cytokinetics (NASDAQ: CYTK) and Tandem Diabetes Care (NASDAQ: TNDM)

Cory Kasimov

Evercore ISI

$80

Buy

28.64%

Upside

Reiterated

02/25/26

Evercore ISI Keeps Their Buy Rating on Cytokinetics (CYTK)

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

02/25/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Evolent Health (NYSE: EVH), Medtronic (NYSE: MDT) and Cytokinetics (NASDAQ: CYTK)

Serge Belanger

Needham

$84→$85

Buy

36.68%

Upside

Reiterated

02/25/26

Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (NASDAQ: DAWN) and Cytokinetics (NASDAQ: CYTK)

Maxwell Skor

Morgan Stanley

$90

Buy

44.72%

Upside

Reiterated

02/25/26

Cytokinetics: Strong Myqorzo Launch, Expanding Market Access, and Upcoming HCM Milestones Underpin Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Salim Syed

Mizuho Securities

$84→$100

Buy

60.80%

Upside

Assigned

03/18/26

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Perspective Therapeutics (NYSE MKT: CATX)

Tessa Romero

J.P. Morgan

$74→$75

Buy

20.60%

Upside

Assigned

03/17/26

JPMorgan ups Cytokinetics target, adds to Analyst Focus ListJPMorgan ups Cytokinetics target, adds to Analyst Focus List

James Condulis

Stifel Nicolaus

$98

Buy

57.58%

Upside

Reiterated

03/17/26

Cytokinetics (CYTK) Gets a Buy from Stifel Nicolaus

Emily Field

Barclays

$87

Buy

39.89%

Upside

Reiterated

03/16/26

Barclays Keeps Their Buy Rating on Cytokinetics (CYTK)

Mayank Mamtani

B. Riley Securities

$108

Buy

73.66%

Upside

Reiterated

03/11/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pliant Therapeutics (NASDAQ: PLRX) and Cytokinetics (NASDAQ: CYTK)

Yasmeen Rahimi

Piper Sandler

$107

Buy

72.05%

Upside

Reiterated

03/09/26

Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Doximity (DOCS)

Ashwani Verma

UBS

$61→$69

Hold

10.95%

Upside

Reiterated

03/06/26

UBS Remains a Hold on Cytokinetics (CYTK)

Leonid Timashev

RBC Capital

$101

Buy

62.41%

Upside

Reiterated

03/05/26

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), Ascendis Pharma (NASDAQ: ASND) and Avalo Therapeutics (NASDAQ: AVTX)

Jason Zemansky

Bank of America Securities

$66→$67

Hold

7.73%

Upside

Reiterated

02/25/26

Cytokinetics price target raised to $67 from $66 at BofACytokinetics price target raised to $67 from $66 at BofA

Jason Butler

Citizens JMP

$88→$96

Buy

54.37%

Upside

Reiterated

02/25/26

Cytokinetics price target raised to $96 from $88 at CitizensCytokinetics price target raised to $96 from $88 at Citizens

Joseph Pantginis

H.C. Wainwright

$136

Buy

118.68%

Upside

Reiterated

02/25/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Cytokinetics (NASDAQ: CYTK) and Tandem Diabetes Care (NASDAQ: TNDM)

Cory Kasimov

Evercore ISI

$80

Buy

28.64%

Upside

Reiterated

02/25/26

Evercore ISI Keeps Their Buy Rating on Cytokinetics (CYTK)

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

02/25/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Evolent Health (NYSE: EVH), Medtronic (NYSE: MDT) and Cytokinetics (NASDAQ: CYTK)

Serge Belanger

Needham

$84→$85

Buy

36.68%

Upside

Reiterated

02/25/26

Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (NASDAQ: DAWN) and Cytokinetics (NASDAQ: CYTK)

Maxwell Skor

Morgan Stanley

$90

Buy

44.72%

Upside

Reiterated

02/25/26

Cytokinetics: Strong Myqorzo Launch, Expanding Market Access, and Upcoming HCM Milestones Underpin Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cytokinetics

3 Months

xxx

Success Rate

11/21 ratings generated profit

Average Return

+26.27%

assigned a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.38% of your transactions generating a profit, with an average return of +26.27% per trade.

1 Year

Salim SyedMizuho Securities

Success Rate

36/51 ratings generated profit

Average Return

+33.32%

assigned a buy rating 2 days ago

Copying Salim Syed's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +33.32% per trade.

2 Years

xxx

Success Rate

14/18 ratings generated profit

Average Return

+26.77%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +26.77% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CYTK Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CYTK has received 33 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. CYTK average Analyst price target in the past 3 months is 92.79.

Each month's total comprises the sum of three months' worth of ratings.

CYTK Financial Forecast

CYTK Earnings Forecast

Next quarter’s earnings estimate for CYTK is -$1.65 with a range of -$1.86 to -$1.37. The previous quarter’s EPS was -$1.50. CYTK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year CYTK has Performed in-line its overall industry.

CYTK Sales Forecast

Next quarter’s sales forecast for CYTK is $7.80M with a range of $3.00M to $23.00M. The previous quarter’s sales results were $17.75M. CYTK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year CYTK has Performed in-line its overall industry.

CYTK Stock Forecast FAQ

What is CYTK’s average 12-month price target, according to analysts?

Based on analyst ratings, Cytokinetics’s 12-month average price target is 92.79.

What is CYTK’s upside potential, based on the analysts’ average price target?

Cytokinetics has 49.20% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CYTK a Buy, Sell or Hold?

Cytokinetics has a consensus rating of Strong Buy which is based on 15 buy ratings, 2 hold ratings and 0 sell ratings.

What is Cytokinetics’s price target?

The average price target for Cytokinetics is 92.79. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $136.00 ,the lowest forecast is $67.00. The average price target represents 49.20% Increase from the current price of $62.19.

What do analysts say about Cytokinetics?

Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of CYTK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Cytokinetics (CYTK) Stock Forecast & Price Target

CYTK Analyst Ratings

CYTK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cytokinetics

CYTK Analyst Recommendation Trends

CYTK Financial Forecast

CYTK Earnings Forecast

CYTK Sales Forecast

CYTK Stock Forecast FAQ

Detailed List of Analyst Forecasts